New Key Statistics Module, Z-Score and F-Score
NAS:IDYA Key Ratios
| Market Cap $ M | 3,845.11 |
| Enterprise Value $ M | 3,045.46 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 3.20 |
| Price/Sales | 15.27 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 234.00 |
| EPS (TTM) $ | -1.94 |
| Beneish M-Score | 26.37 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -15.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -14.04 |
| EV-to-EBITDA | -14.33 |
| PEG | -- |
| Shares Outstanding M | 96.49 |
| Net Margin (%) | -74.75 |
| Operating Margin % | -92.67 |
| Pre-tax Margin (%) | -74.75 |
| Quick Ratio | 10.45 |
| Current Ratio | 10.45 |
| ROA % (ttm) | -15.42 |
| ROE % (ttm) | -16.79 |
| ROIC % (ttm) | -55.24 |
| Dividend Yield % | -- |
| Altman Z-Score | 20.26 |
IDYA Number of Guru Trades
IDYA Volume of Guru Trades
Gurus Latest Trades with NAS:IDYA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:IDYA is held by these investors
Total 1
IDEAYA Biosciences Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:IDYA
2026 Q2
What the manager wrote
We hold Ideaya Biosciences who, working with Roche’s pan-ras inhibitor, are testing its PRMT5 inhibitor in pancreatic patients. Recently, Tango Therapeutic’s PRMT5 inhibitor showed promising early data. However, Ideaya’s molecule, given its design, should have a better therapeutic window. This positions Ideaya favorably in the competitive landscape of pancreatic cancer treatments, suggesting strong potential for future success.
News about NAS:IDYA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers